A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects

NCT05294536 · Completed

Last updated 2026-05-28

This clinical trial compares how two versions of the diabetes medication liraglutide (RD12014 and Victoza®) are absorbed in the bloodstream of healthy Chinese adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 50 people

Who can join Ages 18–45 · male only Healthy volunteers accepted.

Timeline Started 2020-06 · est. completion 2020-11

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05294536 ↗

Description as written by the study sponsor.

To evaluate the pharmacokinetics similarity between the liraglutide injection (RD12014) produced by Sunshine Lake Pharma Co., Ltd. and liraglutide injection (Victoza®) produced by Novo Nordisk Pharmaceutical Co., Ltd for single dose in healthy male subjects, as well as to evaluate the similarity of the safety and immunogenicity between RD12014 and Victoza ® in healthy subjects.

Treatments tested

Liraglutide injection,RD12014 Drug

single dose, s.c. injection
Liraglutide injection,Victoza Drug

single dose, s.c. injection

Main thing measured	Maximum (peak) plasma drug concentration(Cmax)
Sponsor	Sunshine Lake Pharma Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05294536 ↗